Stockreport

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

PDS Biotechnology Corporation  (PDSB) 
Last pds biotechnology corporation earnings: 11/7 06:00 am Check Earnings Report
PDF 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of 80%; Parallel trial without PDS01ADC resulted in 2-y [Read more]